LipiFlow® Treatment for Dry Eye
Suffer from dry eye? Eyeclectic may have the solution you’ve been looking for.
LipiFlow is a proven treatment for dry eye that actually helps restore the natural moisture balance for your eyes.
It is a non-invasive treatment that targets the leading cause of dry eye—meibomian gland disease.
Schedule an appointment at Eyeclectic if you want lasting relief from dry eye.
The Leading Cause of Dry Eye
The eyelids are lined with meibomian glands that release important lubricants to the eye.
If these glands become blocked or fail due to aging or changes in your health, your tears won’t perform the way they should. This condition—meibomian gland disease (MGD)—is the leading cause of dry eye.
MGD can be diagnosed with advanced diagnostic imagery using the OCULUS keratograph 5M. The OCULUS keratograph creates detailed maps and images of both the eye tissue and tear layers. It helps assess eye health and pinpoint underlying causes of dry eye.
If MGD is the cause of your dry eye, then your optometrist may recommend an advanced, painless treatment called LipiFlow.
This state-of-the-art therapy opens blocked ducts and restores gland function. The device uses sophisticated technology to precisely deliver heat, massage, and pressure to the meibomian glands.
Treatments are painless and symptoms improve in as little as two weeks.
How Does LipiFlow Work?
LipiFlow is an FDA-approved medical device for treating meibomian gland disease. It uses precisely controlled therapeutic heat and massage to relieve blockages. LipiFlow is safe and pain-free.
Patented components called Activators deliver treatments directly to the inner and outer eyelids while protecting delicate eye tissue. Sterile and single-use, the Activators are designed for patient safety and comfort.
Each treatment takes about 12 minutes. And most patients find improvement from symptoms in as little as two weeks, but only your eye doctor can guide you on what to expect.
Contact Eyeclectic to find out if LipiFlow can bring relief to your dry eyes.